Preventive role of metformin on peripheral neuropathy induced by diabetes

Lós, Deniele Bezerra; Oliveira, W.; Duarte-Silva, Eduardo; Sougey, Wenddy Wyllie Damascena; Freitas, Elvis da Silva Rodrigues de; Oliveira, Anne Gabrielle Vasconcelos de; Braga, Clarissa Figueredo; França, Maria Eduarda Rocha de; Araújo, Shyrlene Meiry da Rocha; Rodrigues, Gabriel Barros; Rocha, Sura Wanessa Santos; Peixoto, Christina Alves; Moraes, Sílvia Regina Arruda de

doi:10.1016/j.intimp.2019.05.057

Cited by 25 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, metformin can function to prevent the onset of diabetic neuropathy. In an animal study, metformin treatment protected against neural damage by increasing the levels of neural growth factor, vascular endothelial growth factor and anti-inflammatory factors[ 18 ]. Another animal study demonstrated that metformin preserved peripheral nerve fiber density and that the beneficial effects of metformin were comparable with those of alpha lipoic acid, an antioxidant used in the clinical treatment of diabetic neuropathy[ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Min¹,

Kim²,

Choi³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Neuropathy is a common chronic complication in type 2 diabetes mellitus (T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin- or metformin-induced neuropathy. AIM To evaluate the incidence of neuropathy among patients with T2DM associated with statin and metformin therapies. METHODS Korean Health Insurance Review and Assessment national patient sample data from 2016 and 2017 were used. Patients with T2DM and no complications were divided into statin/metformin/statin + metformin users and non-users. Neuropathy incidence was defined by International Statistical Classification of Diseases and Related Health Problems, 10 th revision codes and concomitant prescriptions for anticonvulsants or antidepressants. Logistic regression analyses were conducted to examine the associations between statin/metformin/statin + metformin therapies and the incidence of neuropathy. Propensity score (PS) matching was performed on the basis of age, sex and comorbidities. RESULTS Overall, 34964 and 35887 patients with T2DM and no complications were included in the Korean Health Insurance Review and Assessment national patient sample datasets from 2016 and 2017, respectively. Statin therapy was associated with increased risks of neuropathy in 2016 and 2017 [PS-matched odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.08-1.38; PS-matched OR = 1.17, 95%CI: 1.03-1.33, respectively]. Metformin therapy was associated with reduced risks of neuropathy in 2016 and 2017 (PS-matched OR = 0.30, 95%CI: 0.21-0.42; PS-matched OR = 0.44, 95%CI: 0.32-0.60, respectively). Combined statin + metformin therapy was not significantly associated with neuropathy in 2016 or 2017 (PS-matched OR = 0.85, 95%CI: 0.61-1.19; PS-matched OR = 0.95, 95%CI: 0.66-1.38, respectively). CONCLUSION Statin therapy was associated with enhanced risk of new-onset neuropathy in patients with T2DM, but metformin therapy showed the opposite association.

show abstract

Section: Discussionmentioning

confidence: 99%

Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Min¹,

Kim²,

Choi³

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…Sülfonilüre gurubu andiyabetik ajanlar tip 2 DM'da yaygın olarak kullanılmaktadır ve çeşitli çalışmalarda antioksidan özelliklere sahip olduğu, sıçanlarda diyabet kaynaklı poliol yolu aktivasyonunu ve oksidatif stres artışını inhibe ederek periferik sinir fonksiyon bozukluğunu azalttığı bulunmuştur (11). Metforminin ise inflamatuar sitokinlerin ekspresyonunu inhibe ederek, sinir hücrelerindeki anjiyojenik ve nörotrofik faktörleri arttırdığı periferik sinir hasarını önlediği veya geciktirdiği bildirilmiştir (12).…”

Section: Discussionunclassified

Comparison of Neuropathic Pain Course in Long-Term Oral Antidiabetic and Insulin Use

Yürük

Melek

2020

Mustafa Kemal Üniversitesi Tıp Dergisi

View full text Add to dashboard Cite

Bu çalışmada uzun dönem oral antidiyabetik ve insülin kullanan tip 2 diyabetes mellituslu hastalarda nöropatik ağrının diğer risk faktörleri ile birlikte karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Amerikan Diyabet Cemiyeti kriterlerine göre Tip 2 diyabetes mellitus olan 100 hasta çalışmaya alındı. Hastalara nörolojik muayene yapılıp, L A N S S (Leeds Assesment of Neuropatic Symptoms and Signs) v e M c-Gill Melzack Ağrı Sorgu Formu uygulandı. LANSS ≥12 olan hastalar Nöropatik Ağrılı gurup ve LANSS <12 olan hastalar Nöropatik Ağrısız gurup olarak ayrıldı. Guruplar demografik özellikler, diyabet süresi, kullanılan antidiyabetik tedavi, serum glukoz ve HbA1c değerleri, hipertansiyon ve hiperlipidemi varlığı açısından karşılaştırıldı. Bulgular: Hastaların %51'inde nöropatik ağrı saptandı. Nöropatik Ağrılı gurupta ileri yaş, uzun diyabet süresi, yüksek serum glukoz ve HbA1c düzeyleri, hipertansiyon varlığı Nöropatik Ağrısız gurupla karşılaştırıldığında anlamlı fark bulundu. (P<0.05) Her 2 gurup arasında cinsiyet, hiperlipidemi varlığı, kullanılan antidiyabetik tedavi açısından anlamlı bir fark bulunmadı (P>0.05). Hastalarda nöropatik ağrı lokalizasyonu en sık alt ve üst ekstremite distalinde, paterni paroksismal ve spontan, tanımında en sık kullanılan ifadeler 'sıcaklık veren' 'diken diken' ve en sık tetikleyen faktör anksiyeteydi. Sonuç: Tip 2 diyabetes mellitus hastalarında nöropatik ağrı gelişiminde; ileri yaş, uzun diyabetes mellitus süresi, kötü glisemik kontrol ve hipertansiyon varlığı önemli rol oynamaktadır. Cinsiyet, hiperlipidemi varlığı, kullanılan antidiyabetik tedavi ise nöropatik ağrı gelişiminde farklılık yaratmamaktadır.

show abstract

“…Ma et al reported that Metformin can reduce the symptoms of diabetic neuropathy such as allodynia and hyperalgesia in Streptozocin (STZ) induced diabetic rats [42]. Further studies have suggested that higher doses of Metformin have efficiently reduced the inflammatory cytokines expression and accelerate the nerve repair in STZ-induced diabetic rats [43,44]. Sharma et al reported that Metformin can relief diabetic neuropathy symptoms, exhibit neuroprotective effects and reduce inflammatory factors when used in combination with Sitagliptin in STZ/nicotinamideinduced diabetic rats [45].…”

Section: Pre-clinical Studies On the Treatment Of Pnmentioning

confidence: 99%

Peripheral Neuropathy: A review of mechanism-based treatments with a focus on metformin as a possible choice

Arasteh¹

2023

J Clin Images Med Case Rep

View full text Add to dashboard Cite

show abstract

Preventive role of metformin on peripheral neuropathy induced by diabetes

Cited by 25 publications

References 43 publications

Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Comparison of Neuropathic Pain Course in Long-Term Oral Antidiabetic and Insulin Use

Peripheral Neuropathy: A review of mechanism-based treatments with a focus on metformin as a possible choice

Contact Info

Product

Resources

About